Source comparison
Melanotan 1 vs. Melanotan 2 vs. Alpha-MSH: Receptor Activity Comparison
Understanding where Melanotan 1 fits within the melanocortin peptide family requires direct comparison across receptor binding profiles, half-life, and adverse event patterns observed in research models. Alpha-MSH (endogenous) 0.3 nM 15 nM / 20 nM ~20 min Base
This comparison does not assign a generated winner or score.
- Understanding where Melanotan 1 fits within the melanocortin peptide family requires direct comparison across receptor binding profiles, half-life, and adverse event patterns observed in research models.
- Alpha-MSH (endogenous)
- 0.3 nM
- 15 nM / 20 nM
- ~20 min
- Baseline reference for melanocortin signaling
- None (endogenous baseline)
- Melanotan 1 (afamelanotide)
- 0.5 nM
- 500 nM / 1,000 nM
- ~33 min
- MC1R-selective melanogenesis, photoprotection research
- Nausea (15–20%), injection site reaction (10–15%), minimal systemic effects
- Melanotan 2
- 0.4 nM / 0.3 nM
- ~60 min
- Multi-receptor melanocortin research (MC1R + MC3R/MC4R)
- Nausea (40–50%), spontaneous erections (male models, 30–40%), appetite suppression, cardiovascular changes
- Bremelanotide (PT-141)
- 15 nM
- ~3 hours
- MC3R/MC4R-preferring agonist for CNS melanocortin pathways
- Nausea (40%), hypertension, flushing
- The selectivity ratio is the critical differentiator. Melanotan 1 demonstrates 1,000-fold selectivity for MC1R over MC4R, while Melanotan 2 binds all melanocortin receptors with near-equal affinity. This explains the divergent adverse event profiles: MC3R and MC4R activation in the hypothalamus and brainstem mediate appetite, sexual arousal, cardiovascular tone, and nausea signaling. Research models receiving Melanotan 2 exhibit nausea rates of 40–50% due to direct MC4R activation in the area postrema (the brain's chemoreceptor trigger zone), compared to 15–20% nausea rates with Melanotan 1, which occurs primarily as a peripheral effect from gastrointestinal MC1R activation rather than central nervous system pathways.
- Another practical distinction involves visual confirmation of receptor engagement. Both peptides darken skin pigmentation, but Melanotan 2's MC4R activity also darkens existing nevi (moles) and can induce new hyperpigmented lesions due to stimulation of MC4R-expressing neural crest-derived cells. Melanotan 1 produces more uniform pigmentation across normal melanocytes without disproportionate nevus darkening. A difference that matters for photoprotection research models where uneven pigmentation confounds UV damage assessment.
- For labs conducting isolated melanogenesis research without confounding appetite, sexual, or cardiovascular variables, Melanotan 1's receptor selectivity provides cleaner experimental conditions. For studies specifically investigating MC4R-mediated pathways (energy homeostasis, feeding behavior), Melanotan 2 becomes the appropriate tool. The choice depends on whether the research question targets peripheral melanocyte biology or central melanocortin pathways.